New Horizons in KRAS-Mutant Lung Cancer: Dawn After Darkness

In non-small cell lung cancer (NSCLC), the most frequent oncogenic mutation in western countries is KRAS, for which, however, there remains no clinically approved targeted therapies. Recent progress on high biological heterogeneity including diverse KRAS point mutations, varying dependence on mutant...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Haitang, Liang, Shun-Qing, Schmid, Ralph A., Peng, Ren-Wang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773824/
https://www.ncbi.nlm.nih.gov/pubmed/31612108
http://dx.doi.org/10.3389/fonc.2019.00953

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773824/
https://www.ncbi.nlm.nih.gov/pubmed/31612108
http://dx.doi.org/10.3389/fonc.2019.00953

Ejemplares similares